Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma

TUESDAY, Feb. 3, 2026-- For patients with desmoplastic melanoma, neoadjuvant treatment with pembrolizumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, results in a pathological complete response rate of 71 percent, according to a...